Ocugen to Present on Modifier Gene Therapy Platform at : vim

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering,...

Related Keywords

, Nieraj Jain , Tarun Upadhyay , Joses Pulido , Murthy Chavali , Shankar Musunuri , Borooah Shyamanga , Benjamin Bakall , Arunk Upadhyay , Nalin Mehta , Sahar Matloob , Paul Yang , University Of Miami , Ocugen Inc , Head Of Research Development , Seattle Convention Center , Nuclear Hormone Receptor , Exchange Commission , Head Of Communications , Association For Research , Linkedin , Clinical Development , Hormone Receptor Based Gene Modifier Therapy , Retinitis Pigmentosa Associated , Byron Lam , Endowed Chair , March Building , Gene Agnostic Modifier Therapy , Retinitis Pigmentosa , Study Results , Melight Study Design , Chief Scientific Officer , Show Floor , Educational Lounge , Multifactorial Therapeutic Intervention , Dry Age Related Macular Degeneration , Huma Qamar , Chief Medical Officer , Novel Modifier Approach , Orphan Receptor , Private Securities Litigation Reform Act , Nasdaq Ocgn , Ocugen , Biotechnology , Ophthalmology , Gene Therapy ,